Literature DB >> 656862

Progress in myeloma at last.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 656862      PMCID: PMC1605439     

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  9 in total

Review 1.  Plasma cell myeloma. An interpretive review.

Authors:  D E Bergsagel
Journal:  Cancer       Date:  1972-12       Impact factor: 6.860

2.  Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU.

Authors:  B J Lee; G Sahakian; B D Clarkson; I H Krakoff
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

3.  Tumor size, sensitivity to therapy, and design of treatment schedules.

Authors:  L Norton; R Simon
Journal:  Cancer Treat Rep       Date:  1977-10

4.  Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.

Authors:  D C Case; D J Lee; B D Clarkson
Journal:  Am J Med       Date:  1977-12       Impact factor: 4.965

5.  Exchangeable intracellular methotrexate levels in the presence and absence of vincristine at extracellular drug concentrations relevant to those achieved in high-dose methotrexate-folinic acid "rescue" protocols.

Authors:  I D Goldman; V Gupta; J C White; S Loftfield
Journal:  Cancer Res       Date:  1976-01       Impact factor: 12.701

6.  Expansion of the growth fraction in multiple myeloma with alkylating agents.

Authors:  S E Salmon
Journal:  Blood       Date:  1975-01       Impact factor: 22.113

7.  Combination therapy for multiple myeloma.

Authors:  R Alexanian; S Salmon; J Bonnet; E Gehan; A Haut; J Weick
Journal:  Cancer       Date:  1977-12       Impact factor: 6.860

8.  Radioimmunoassay for myeloma idiotype.

Authors:  S Gailani; B K Seon; A Nussbaum; E S Henderson; D Pressman
Journal:  J Natl Cancer Inst       Date:  1977-06       Impact factor: 13.506

9.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.